These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26063948)

  • 1. Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia.
    Hu M; Yang YL; Masuda D; Yamashita S; Tomlinson B
    Dis Markers; 2015; 2015():154014. PubMed ID: 26063948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
    Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
    Bays HE; Shah A; Lin J; McCrary Sisk C; Paolini JF; Maccubbin D
    J Clin Lipidol; 2010; 4(6):515-21. PubMed ID: 21122699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release niacin (nicotinic acid)/laropiprant.
    Perry CM
    Drugs; 2009 Aug; 69(12):1665-79. PubMed ID: 19678716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Extended-Release Niacin and Extended-Release Niacin/Laropiprant on the Pharmacokinetics of Simvastatin in Healthy Subjects.
    Lauring B; Dishy V; De Kam PJ; Crumley T; Wenning L; Liu F; Sisk C; Wagner J; Lai E
    Am J Ther; 2015; 22(5):367-76. PubMed ID: 24832384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia.
    Sonmez A; Dogru T; Tasci I; Yilmaz MI; Pinar M; Naharci I; Bingol N; Kilic S; Demirtas A; Bingol S; Ozgurtas T; Erikci S
    Clin Endocrinol (Oxf); 2006 May; 64(5):567-72. PubMed ID: 16649978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
    Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin, an old drug with new perspectives for the management of dyslipidaemia.
    Benhalima K; Muls E
    Acta Clin Belg; 2010; 65(1):23-8. PubMed ID: 20373594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release niacin/laropiprant for lipid management: observational study in clinical practice.
    Steinhagen-Thiessen E; Dänschel W; Buffleben C; Smolka W; Pittrow D; Hildemann SK
    Int J Clin Pract; 2013 Jun; 67(6):527-35. PubMed ID: 23437867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
    Aye MM; Kilpatrick ES; Afolabi P; Wootton SA; Rigby AS; Coady AM; Sandeman DD; Atkin SL
    Diabetes Obes Metab; 2014 Jun; 16(6):545-52. PubMed ID: 24401089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial.
    Nasser Figueiredo V; Vendrame F; Colontoni BA; Quinaglia T; Roberto Matos-Souza J; Azevedo Moura F; Coelho OR; de Faria EC; Sposito AC
    Clin Ther; 2014 Jun; 36(6):961-6. PubMed ID: 24768191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.
    Dubé MP; Wu JW; Aberg JA; Deeg MA; Alston-Smith BL; McGovern ME; Lee D; Shriver SL; Martinez AI; Greenwald M; Stein JH;
    Antivir Ther; 2006; 11(8):1081-9. PubMed ID: 17302378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of laropiprant on niacin-induced flushing.
    Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB
    Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.
    Maccubbin D; Tipping D; Kuznetsova O; Hanlon WA; Bostom AG
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):582-9. PubMed ID: 20299362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
    Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
    J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
    McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
    J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
    Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
    Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics of cutaneous flushing response to niacin/laropiprant combination in Hong Kong Chinese patients with dyslipidemia.
    Hu M; Yang YL; Chan P; Tomlinson B
    Pharmacogenomics; 2015; 16(12):1387-97. PubMed ID: 26226939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.